The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditure of $2,693,312 ...

Billing and Ordering TRIESENCE TRIESENCE (J3300 Injection, triamcinolone acetonide, preservative-free, 1 mg) is a single-use ...

Sixteen new projects and 10 continuing projects at 17 universities, as well as two career development awards, have been granted $2,693,312 in expenditures approved  by the board of directors of the ...

Harrow a annoncé que les Centers for Medicare & Medicaid Services ont approuvé la demande de prise en charge transitoire de ...

Billing and Ordering TRIESENCE TRIESENCE (J3300 Injection, triamcinolone acetonide, preservative-free, 1 mg) is a single-use vial of 40 milligrams or 40 units based on the HCPCS descriptor.

B. Riley est positif et recommande le titre à l'achat. L'objectif de cours est modifié à la baisse et passe de 69 USD à 65 ...

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

Harrow, Inc. offers speculative gains from $20s to $30s, with Q4 growth, bullish 2025 revenue guidance, and long-term growth ...

Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will ...

Chardan Capital reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research note published on Friday morning,Benzinga reports. Chardan Capital currently has a ...

at 07:05 Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL Harrow , a leading North American eyecare ...